Zheng Shu-Shen, Huang Dong-Sheng, Wang Wei-Lin, Liang Ting-Bo, Zhang Min, Shen Yan, Xu Xiao, Wu Jian, Yan Sheng, Guo Hua, Lu An-Wei
Department of Hepatobiliary Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Hepatobiliary Pancreat Dis Int. 2002 Feb;1(1):8-13.
To summarize the experience of human orthotopic liver transplantation (OLTx) in treatment of patients with end-stage hepatic disease and their perioperative management.
A retrospective analysis was made on OLTx performed in 77 patients from April 1993 to September 2001 in our department included combined liver-kidney transplantation (6 patients) and living related liver transplantation (2). Among them, 76 were adults and 1 was infant (67 males and 10 females). The donors included 75 non-heart beating donors and 2 living related donors. Veno-venous bypass was used only in 45 cases during the operation. immunosuppressive agents consisted of cyclosporine, cellcept, ALG corticosteroids and FK506.
The one-year survival rates of grafts and recipients with benign hepatic disease were 75%. The recipients this year are surviving with good function of grafts.
Liver transplantation is the best therapeutic method for a large number of patients with end-stage hepatic disease in China.